PharmTech Online Industry Pipeline

May 23rd 2025

Transformations in Drug Development for Cell and Gene Therapies

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its early-stage neurology pipeline.

FDA Refines Regulatory Pathway for Canadian Drug Importation

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

The world logistics background or transportation Industry or shipping business, Container Cargo shipment , truck delivery, airplane , import export Concept | Image Credit: © sittinan.

May 22nd 2025

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

FDA announced efforts to streamline its drug importation process to help U.S. states and Native American tribes access lower-cost Canadian drugs while maintaining safety standards.

IND Application Cleared for Phase II Trial of Grifols’ Dry Eye Disease Drops

FDA on paper texture | Image Credit: © Araki Illustrations.

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Grifols received FDA clearance to begin a Phase II trial of GRF312, an immunoglobulin eye drop for dry eye disease, aiming to improve current treatments.

Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

Patrick Lavery

Sanofi to Acquire Vigil Neuroscience to Expand Neurodegenerative Disease Pipeline

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.

Related Content

May 23rd 2025

Transformations in Drug Development for Cell and Gene Therapies

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its early-stage neurology pipeline.

FDA Refines Regulatory Pathway for Canadian Drug Importation

May 22nd 2025

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

FDA announced efforts to streamline its drug importation process to help U.S. states and Native American tribes access lower-cost Canadian drugs while maintaining safety standards.

IND Application Cleared for Phase II Trial of Grifols’ Dry Eye Disease Drops

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Grifols received FDA clearance to begin a Phase II trial of GRF312, an immunoglobulin eye drop for dry eye disease, aiming to improve current treatments.

Patrick Lavery